Feed CSLLY
CS

CSL Limited CSLLY · OTC

$34.47 +0.19% (+$0.07)

Market cap
$130.1B
Enterprise value
$139.5B
P/E
-
Forward P/E
43.3x
PEG
-
P/S
8.3x
P/FCF
45.2x
EV/EBITDA
27.5x
ROIC
10.0%
Gross margin
47.7%
Net margin
-16.4%
Dividend yield
2.16%
Payout ratio
-
Net debt/EBITDA
1.8x
Beta
0.08
Free float
100.0%

About the company

CSL Limited is an Australian biotechnology company headquartered in Melbourne and one of the world’s leading developers and manufacturers of plasma-derived therapies, vaccines, and biotherapeutics. Founded in 1916 as a government laboratory, it now operates globally through its subsidiaries CSL Behring and CSL Seqirus. The company focuses on treating rare and serious conditions such as blood clotting disorders, immune deficiencies, respiratory diseases, and neurological disorders, while also being one of the largest producers of influenza vaccines worldwide. CSL emphasizes innovation, scientific research, and the advancement of biomedical technologies, with its products available in over 100 countries.

Sector

Healthcare

Industry

Biotechnology

CEO

Gordon Naylor DipCompSc

Employees

29,000

Headquarters

Melbourne

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy